People in the News

Exai Bio, a company developing RNA and AI-enabled liquid biopsy for early cancer detection, has appointed Karen Knudsen to its board of directors. Knudsen is the former CEO of the American Cancer Society and its affiliate, the American Cancer Society Cancer Action Network. Prior to leading ACS, Knudsen served as executive VP of oncology services and enterprise director of the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. She also served as president of the Association of American Cancer Institutes and was a member of the National Cancer Institute's board of scientific advisors.

Acuamark Diagnostics (AcuamarkDx), an early cancer detection company, has added Tim Gordon and Chiara Gabbi to its board of directors.

Gordon has 40 years of experience at Ernst & Young in audit and financial advisory services for both US-based and global health and life sciences companies. He is a graduate of Harvard Business School's Advanced Management Program.

Gabbi is a physician-scientist with more than 20 years of experience in clinical and translational medicine in metabolic diseases, hepatology, cancer, personalized medicine, and genomics. She holds a PhD in medical science from Karolinska Institutet, an MD with specialization in internal medicine from the University of Modena and Reggio Emilia, and a certificate in clinical research from Harvard Medical School.

Amoolya Singh has been named chief technology officer of cancer liquid biopsy firm Delfi Diagnostics. She joins the company from Grail, where she was senior VP of data science and CSO. Prior to that, she was head of discovery technologies at Calico, Alphabet's drug discovery company, and VP of R&D at Amyris. Singh holds a PhD in computational biology and an MS in computer science from the University of California, Berkeley, and a BS in biology and computer science from Carnegie Mellon University. She also completed postdoctoral fellowships at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and at Emory University and worked as a software engineer at various companies.

Jeffrey Vacirca has joined the board of directors of Caris Life Sciences. He is the CEO and chairman of the board of New York Cancer & Blood Specialists and the medical director for oncology network development at Mt. Sinai Health Network. He also founded the Conquering Cancer PAC and cofounded OneOncology and Odonate Therapeutics. Vacirca holds an MD from St. George's University School of Medicine.

Laboratory Corporation of America said EVP and CFO Glenn Eisenberg is retiring from the company on Dec. 2 and Julia Wang will replace him in those roles. Eisenberg will remain at the company as special advisor to the CEO through April 2025.

Wang was previously CFO of BeiGene, which she joined in 2020 as SVP, enterprise optimization and deputy CFO. Prior to that she was SVP, global business finance and corporate planning at Alexion Pharmaceuticals. Before that she held leadership positions at Quest Diagnostics and Johnson & Johnson.

Heidi Chen has been appointed as chief legal officer and corporate secretary of GeneDx, effective Nov. 25. She joins the genome diagnostics company from Zoetis, where she was general counsel after the firm spun off from Pfizer in 2013. Prior to that, she held various leadership positions on Pfizer's legal team, and before that, she worked at Hughes & Hubbard and Clifford Chance. Chen holds a JD from Cornell Law School and a BS from Yale University.

BillionToOne has appointed three new executives: Judy Wong, who previously held leadership positions at Vivani Medical, HeartFlow, and Abaxis, joins the next-generation molecular diagnostics company as VP and controller; Alex Bisignano, who was the founder of Phosphorus and Recombine, will be VP of business development; and Susan Lin, who has expertise in building scalable, compliant, and secure technology infrastructures for precision medicine companies, joins the firm as VP of information systems.

NeoGenomics has appointed Felicia Williams to its board of directors effective Nov. 1, 2024. Williams is a former interim CFO of Macy's and a fellow of the program CEO Action for Racial Equality. She will serve as a member of the board's audit and finance and nominating and corporate governance committees. Besides Macy's, Williams has held financial positions at multinational corporations including Coca-Cola and Bristol Myers-Squibb. She is also a member of the board of directors of Paycom and Anywhere Real Estate.

Standard BioTools has appointed Alex Kim as its CFO, effective Nov. 1. He is a cofounder of the company and was most recently its chief operating officer. Earlier, he was president of Milliken's Healthcare Division, and before that, Kim was SVP of strategy and business development at Pall. Prior to that, he worked in various roles in general management, M&A, and business development at Danaher.

Additionally, Standard BioTools' VP and Corporate Controller Jonathan Mickelsen has been appointed as VP and chief accounting officer.

Epigenetics company Volition has appointed Timothy Still as chairman of the board. Still is currently chairman and CEO of Tstill Enterprises and an operating partner with Revival Healthcare. His most recent operating role was as president and CEO of Sense Biodetection, which merged with Sherlock Biosciences in early 2023. Prior to that, Still was a CEO and/or board member at numerous medical technology companies including Myoscience, MDx Health, Gold Standard Diagnostics, Global Kinetics, Xagenic, and Accumetrics. Earlier in his career, he held senior leadership roles at HemoSense, Cholestech, and Boehringer Mannheim/Roche. Still holds a master's degree in business administration from the University of Southern California and a bachelor of science degree from the University of California, Davis.